BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31515514)

  • 1. Effect of early-stage autophagy inhibition in BRAF
    Zahedi S; Fitzwalter BE; Morin A; Grob S; Desmarais M; Nellan A; Green AL; Vibhakar R; Hankinson TC; Foreman NK; Mulcahy Levy JM
    Cell Death Dis; 2019 Sep; 10(9):679. PubMed ID: 31515514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors.
    Mulcahy Levy JM; Foreman NK; Thorburn A
    Autophagy; 2014; 10(11):2077-8. PubMed ID: 25484091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.
    Levy JM; Thompson JC; Griesinger AM; Amani V; Donson AM; Birks DK; Morgan MJ; Mirsky DM; Handler MH; Foreman NK; Thorburn A
    Cancer Discov; 2014 Jul; 4(7):773-80. PubMed ID: 24823863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells.
    Ahn JH; Lee YW; Ahn SK; Lee M
    Life Sci; 2014 May; 104(1-2):38-46. PubMed ID: 24721513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E-dependent role of autophagy in uveal melanoma.
    Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors.
    Mulcahy Levy JM; Zahedi S; Griesinger AM; Morin A; Davies KD; Aisner DL; Kleinschmidt-DeMasters BK; Fitzwalter BE; Goodall ML; Thorburn J; Amani V; Donson AM; Birks DK; Mirsky DM; Hankinson TC; Handler MH; Green AL; Vibhakar R; Foreman NK; Thorburn A
    Elife; 2017 Jan; 6():. PubMed ID: 28094001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
    Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
    Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
    Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
    Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
    Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
    Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF alterations in primary brain tumors.
    Maraka S; Janku F
    Discov Med; 2018 Aug; 26(141):51-60. PubMed ID: 30265855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
    Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip¹.).
    Jang GH; Lee M
    Life Sci; 2014 Apr; 102(1):41-8. PubMed ID: 24625733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
    Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y
    Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.
    Li YY; Wu C; Chen SM; Shah SS; Wangpaichitr M; Feun LG; Kuo MT; Suarez M; Prince J; Savaraj N
    Oncotarget; 2016 Apr; 7(14):17665-80. PubMed ID: 26771234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation.
    Li YY; Wu C; Shah SS; Chen SM; Wangpaichitr M; Kuo MT; Feun LG; Han X; Suarez M; Prince J; Savaraj N
    Mol Oncol; 2017 Dec; 11(12):1806-1825. PubMed ID: 29094484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF
    Gabler L; Lötsch D; Kirchhofer D; van Schoonhoven S; Schmidt HM; Mayr L; Pirker C; Neumayer K; Dinhof C; Kastler L; Azizi AA; Dorfer C; Czech T; Haberler C; Peyrl A; Kumar R; Slavc I; Spiegl-Kreinecker S; Gojo J; Berger W
    Acta Neuropathol Commun; 2019 Aug; 7(1):128. PubMed ID: 31391125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.